Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The Levulan Kerastick Vehicle is a topical pharmaceutical formulation used as a placebo control in clinical trials evaluating Levulan Photodynamic Therapy (PDT). Developed by DUSA Pharmaceuticals (now a subsidiary of Sun Pharma), this vehicle contains the inactive ingredients found in the Levulan Kerastick (aminolevulinic acid HCl 20% topical solution)—including alcohol, isopropyl alcohol, polyethylene glycol, and water—but lacks the active photosensitizing agent, aminolevulinic acid. In clinical studies for actinic keratosis, the vehicle is applied to the face or scalp and followed by illumination with a blue light source, such as the BLU-U Blue Light Photodynamic Therapy Illuminator. This procedure serves as a control to isolate the therapeutic efficacy and safety of the active drug from the potential effects of the vehicle components and the light treatment itself.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Levulan Kerastick Vehicle.